Anti-annexin A1 antibodies
View Patent ↗Anti-annexin A1 antibodies are provided and methods of treating FAP and cancer using Anti-annexin A1 antibodies, antibody fragments or fusion proteins, including bispecific antibodies targeting two different annexin A1 epitopes, are also provided.
1. An antibody which binds annexin A1, or an annexin A1-binding fragment thereof, or an annexin A1-binding fusion protein, comprising: a) a heavy chain comprising: CDR1 comprising the amino acid sequence in SEQ ID NO:2; CDR2 comprising the amino acid sequence in SEQ ID NO:4; CDR3 comprising the amino acid sequence in SEQ ID NO:6; and a light chain comprising: comprising the amino acid sequence in SEQ ID NO:8; CDR2 comprising the amino acid sequence SAS, SEQ ID NO:10; CDR3 comprising the amino acid sequence in SEQ ID NO:12; or
b) a heavy chain comprising: CDR1 comprising the amino acid sequence in SEQ ID NO:14; CDR2 comprising the amino acid sequence in SEQ ID NO:16; CDR3 comprising the amino acid sequence in SEQ ID NO:18; and a light chain comprising: CDR1 comprising the amino acid sequence in SEQ ID NO:20; CDR2 comprising the amino acid sequence DTS, SEQ ID NO:22; CDR3 comprising the amino acid sequence in SEQ ID NO:24; or
c) a heavy chain comprising: CDR1 comprising the amino acid sequence in SEQ ID NO:26; CDR2 comprising the amino acid sequence in SEQ ID NO:28; CDR3 comprising the amino acid sequence in SEQ ID NO:30; and a light chain comprising: CDR1 comprising the amino acid sequence in SEQ ID NO:32; CDR2 comprising the amino acid sequence GAT, SEQ ID NO:34; CDR3 comprising the amino acid sequence in SEQ ID NO:36.
2. The antibody, annexin A1-binding fragment, or fusion protein of claim 1 , wherein the heavy chain comprising: CDR1 comprising the amino acid sequence in SEQ ID NO:2; CDR2 comprising the amino acid sequence in SEQ ID NO:4; CDR3 comprising the amino acid sequence in SEQ ID NO:6; and a light chain comprising: comprising the amino acid sequence in SEQ ID NO:8; CDR2 having the sequence SAS, SEQ ID NO:10; CDR3 comprising the amino acid sequence in SEQ ID NO:12.
3. The antibody of claim 1 , wherein the antibody is a monoclonal antibody.
4. The antibody, annexin A1-binding fragment, or fusion protein of claim 1 , comprising framework regions of a light chain and/or a heavy chain which are human framework regions, or have 85% or more sequence identity thereto.
5. The antibody, annexin A1-binding fragment, or fusion protein of claim 4 , wherein the framework regions of the light chain and/or the heavy chain are human framework regions.
6. The antibody of claim 1 , wherein the antibody is a humanized antibody.
7. The antibody or annexin A1-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment thereof has a human sequence Fc region.
8. A nucleic acid encoding a heavy chain of claim 1 .
9. A nucleic acid encoding a light chain of claim 1 .
10. The nucleic acid of claim 8 , which is an expression vector.
11. An antibody which binds annexin A1 comprising the complementary-determining regions (CDRs), wherein each of the CDRs has an amino acid sequence as follows: CDR1 comprising the amino acid sequence in SEQ ID NO: 2; CDR2 comprising the amino acid sequence in SEQ ID NO: 4; CDR3 comprising the amino acid sequence in SEQ ID NO: 6; CDR4 comprising the amino acid sequence in SEQ ID NO: 8; CDR5 comprising the amino acid sequence SAS, SEQ ID NO:10; and CDR6 comprising the amino acid sequence in SEQ ID NO: 12.
12. The antibody of claim 11 , wherein the antibody is a monoclonal antibody.